Spread of Vancomycin-Resistant Enterococci: Why Did It Happen in the United States?

Infection Control and Hospital Epidemiology

Volumn 19, Issue 8, 1998, Pages 539-545

  Martone, William J ^a  

^a National Foundation for Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CROSS INFECTION; DISEASE CARRIER; DISEASE TRANSMISSION; DRUG EFFECT; ENTEROCOCCUS; GROWTH, DEVELOPMENT AND AGING; HETEROZYGOTE; HOSPITAL; HUMAN; INFECTION CONTROL; METHODOLOGY; REVIEW; STANDARD; STATISTICS; UNITED STATES;

ANTI-BACTERIAL AGENTS; CARRIER STATE; CROSS INFECTION; DISEASE RESERVOIRS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; INFECTION CONTROL; UNITED STATES; VANCOMYCIN;

EID: 0032130468     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.2307/30141777     Document Type: Article

References (72)

1. Toala P, McDonald A, Wilcox C, Finland M. Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro with special reference to species differences. Am J Med Sci 1969;258:416-430.
2. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-161.
3. Uttley AHC, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-181.
4. Lequercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-556.
5. Murray B. Editorial response: what can we do about vancomycin-resistant enterococci? Clin Infect Dis 1995;20:1134-1136.
6. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033-1048.
7. Boyle JF, Soumakis SA, Rendo A. Herrington JA, Gianarkis DG, Thurberg BE, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-1285.
8. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
9. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-755.
10. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700-705.
11. Livornese LL, Dias S, Samel C, Romanowski B, Taylor S, May P, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-116.
12. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994;32:1148-1153.
13. Beezhold DW, Slaughter S, Hayden MK, Matushek M, Nathan C, Trenholme GM, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704-706.
14. Slaughter S, Hayden MK, Nathan C. et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448-456.
15. Tornieporth NG, Roberts RB, John J, Hafner A, Riley L. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-772.
16. Dembry LM, Uzokwe K, Zervos MJ. Control of endemic glycopeptide-resistant enterococci. Infect Control Hosp Epidemiol 1996;17:286-292.
17. Gordts B, Van Landuyt H, Ieven M, Vandamme P, Goossens H. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol 1995;33:2842-2846.
18. Moreno F, Grota P, Crisp C, Magnon K, Melcher GP, Jorgensen JH, et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis 1995;21:1234-1237.
19. Morris JG, Shay DK, Hebden JN, McCarter RI, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-259.
20. Pegues DA, Pegues CF, Hibberd PL, Ford DS, Hooper DC. Emergence and dissemination of a highly vancomycin-resistant vanA. strain of Enterococcus faecium at a large teaching hospital. J Clin Microbiol 1997;35:1565-1570.
21. Porwancher R, Sheth A, Remphrey S, Taylor E, Hinkle C, Zervos M. Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: possible transmission by an electronic ear-probe thermometer. Infect Control Hosp Epidemiol 1997;18:771-773.
22. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-1025.
23. Rafferty ME, McCormick MI, Bopp LH, Baltch AL, George M, Smith RP, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997;18:342-344.
24. Rao GG, Ojo F, Kolokithas D. Vancomycin-resistant gram-positive cocci: Risk factors for faecal carriage. J Hosp Infect 1997;35:63-69.
25. Ena J, Dick RW, Jones RN, Wenzel RP The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598-602.
26. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757-765.
27. Edlund C, Barkholt L, Olsson-Uljequist B, Nord CE. Effect of vancomycin on the intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997;25:729-732.
28. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:1129-1136.
29. Boyce JM, Mermel LA, Zervos MJ, Rice LB, Potter-Bynoe G, Giorgio C, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634-637.
30. Bonilla HF, Zervos MA, Lyons MJ. Bradley SF, Hedderwick SA, Ramsey MA, et al. Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute-care hospital. Infect Control Hosp Epidemiol 1997;18:333-339.
31. Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-1133.
32. Roghmann MC, McCarter RJ, Brewrink J, Cross AS, Morris JG, Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 1997;25:1056-1059.
33. Tucci V, Haran MA, Isenberg HD. Epidemiology and control of vancomycin-resistant enterococci in an adult and children's hospital. Am J Infect Control 1997;25:371-376.
34. McNeeley DF, Brown AE, Noel GJ, Chung M, de Lencastre H. An investigation of vancomycin-resistant Enterococcus faecium within the pediatric service of a large urban medical center. Pediatr Infect Dis J 1998;17:184-188.
35. Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-685.
36. Montecalvo MA, Shay DK, Gedris C, Petrullo C, Uman J, Rodney K, et al. A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: colonized patients pose an infection control risk. Clin Infect Dis 1997;25:929-930.
37. Yamaguchi E, Valena F, Smith SM, Simmons A, Eng RHK. Colonization pattern of vancomycin-resistant Enterococcus faecium. Am J Infect Control 1994;22:202-206.
38. Linden P, Pasculle AW, Kramer DJ, Kusner S, Manez R. The duration of fecal carriage on vancomycin-resistant Enterococcus faecium (VREF). The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy: Orlando, FL; October 1994. Abstract J150.
39. Polish L, Hebden J, Shay D, Jarvis W, Schwalbe R, Morris JG Jr. Duration of fecal carriage of vancomycin-resistant enterococci (VRE) in ICU patients. The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 1995. Abstract J37.
40. Henning K, Eagan J, Boone N, Brown AE, Wollner N, de Lencastre H, et al. Stool surveillance for vancomycin-resistant Enterococcus faecium (VREF) on a pediatric oncology ward: duration of shedding and incidence of clinical infections. The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 1995. Abstract J38.
41. Roghmann MC, Qaiyumi S, Johnson JA, Schwalbe R, Morris JG. Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. Clin Infect Dis 1997;24:514-515.
42. Lai KK, Fontecchio SA, Kelley AL, Melvin ZS, Baker S. The epidemiology of fecal carriage of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:762-765.
43. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
44. Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.
45. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
46. Noskin GA, Stosor V, Cooper I, Peterson LR Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995;16:577-581.
47. Anderson RL, Carr JH, Bond WW, Favero MS. Susceptibility of vancomycin-resistant enterococci to environmental disinfectants. Infect Control Hosp Epidemiol 1997;18:195-199.
48. Saurina G, Landmann D, Quale JM. Activity of disinfectants against vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1997;18:345-347.
49. Bradley CR, Fraise AP. Heat and chemical resistance of enterococci. J Hosp Infect 1996;34:191-196.
50. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adal KA, Farr BM. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1998;19:261-264.
51. Torell E, Fredlund H, Tornquist E, Myhre EB, Sjoberg L, Sundsfjord A. Intrahospital spread of vancomycin-resistant Enterococcus faecium in Sweden. Scand J Infect Dis 1997;29:259-263.
52. McNeil MM, Solomon SL. The epidemiology of methicillin-resistant Staphylococcus aureus. Antimicrobic Newsletter 1985;2:49-56.
53. Chow JW, Kuritza A, Shlaes DM, Green M, Sahm DF, Zervos MJ. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J Clin Microbiol 1993;31:1609-1611.
54. Tenover FC, Tokars J, Swenson J, Paul S, Spitalny K, Jarvis W. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol 1993;31:1695-1699.
55. Webb R, Currier M, Brackin B, Nolan R, Wilson J. Capability to identify vancomycin resistant enterococci (VRE) and other emerging pathogens in clinical microbiology laboratories serving a rural state. Infect Control Hosp Epidemiol 1997;18:(suppl)P23. Abstract.
56. Swenson JM, Ferraro MJ, Sahm DF, Charache P, the National Committee for Clinical Laboratory Standards Working Group on Enterococci, Tenover FC. New vancomycin disk diffusion breakpoints for enterococci. J Clin Microbiol 1992;30:2525-2528.
57. Swenson JM, Clark NC, Ferraro MJ, Sahm DF, Doern G, Pfaller MA, et al. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol 1994;32:1700-1704.
58. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. Villanova, PA: National Committee for Clinical Laboratory Standards; 1993.
59. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A5. Villanova, PA: National Committee for Clinical Laboratory Standards; 1993.
60. Ribeiro J, Chenevert C, Miller N, Boyce J. Prevalence of vancomycin-resistant enterococci (VRE) among nursing home residents (NHR) admitted to a university-affiliated hospital. Infect Control Hosp Epidemiol 1997;18:(suppl)P23. Abstract.
61. Revuelta MP, Nord JA, Yarrish RL, Kislak JW, LaBombardi V. Recycling of hospital-acquired colonization with vancomycin resistant enterococci via nursing home residents. Clin Infect Dis 1995;21:730. Abstract.
62. Sargent SJ, Baselski VS, Reed LD, Wong L, Sahm DF. Simultaneous hospital and community emergence of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995;21:729. Abstract.
63. Bates J. Epidemiology of vancomycin-resistant enterococcus in the community and the relevance of farm animals to human infection. J Hosp Infect 1997;37:89-101.
64. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605-2609.
65. Semmelweis I. The Etiology, the Concept, and the Prophylaxis of Childbed Fever. Pest, CA: Hartlben's Verlag-Expedition; 1861. Translated by FP Murphy and republished, Classics of Medicine Library, Birmingham, AL; 1981.
66. Larson E, Kretzer EK. Compliance with handwashing and barrier precautions. J Hosp Infect 1995;30:88-106.
67. Jarvis WR. Handwashing - the Semmelweis lesson forgotten? Lancet 1994;344:1311-1312.
68. Voss A, Widmer AF. No time for handwashing!? Handwashing versus alcoholic rub: can we afford 100% compliance? Infect Control Hosp Epidemiol 1997;18:205-208.
69. Larson E, McGeer A, Quraishi A, Krenzischek D, Parsons BJ, Holdford J, et al. Effect of an automated sink on handwashing practices and attitudes in high-risk units. Infect Control Hosp Epidemiol 1991;12:422-428.
70. Maki DG, Zilz MA, McCormick R. The effectiveness of using pre-emptive barrier precautions routinely (protective isolation) in all high-risk patients to prevent nosocomial infection with resistant organisms, especially MRSA, VRE, and C difficile. The 34th Annual Meeting of the Infectious Diseases Society of America; New Orleans, LA; September 1996. Abstract 43.
71. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234-240.
72. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. MMWR 1997;46:813-815.